Natera, Inc. (NTRA), a diagnostics company, Monday announced that it has acquired the non-invasive pre-natal screening and carrier screening business of medical genetics company, Invitae (NVTA).
StockNews.com upgraded shares of Invitae (NYSE:NVTA – Free Report) from a sell rating to a hold rating in a research note published on Friday. Separately, The Goldman Sachs Group decreased their price target on Invitae from $1.00 to $0.50 and set a sell rating on the stock in a research note on Friday, October 20th. […]
StockNews.com lowered shares of Invitae (NYSE:NVTA – Free Report) from a hold rating to a sell rating in a research report released on Monday. NVTA has been the subject of several other reports. The Goldman Sachs Group decreased their price objective on shares of Invitae from $1.00 to $0.50 and set a sell rating for […]